A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Adenocarcinoma of the Rectum · Locally Advanced Rectal Adenocarcinoma · Rectal Adenocarcinoma · HER2 Positive Rectal Adenocarcinoma · Rectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

    Contact: Study coordinator (Andrea Cercek, MD) · 646-888-4189
    Contact: Principal Investigator (Andrea Cercek, MD)
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

    Contact: Study coordinator (Andrea Cercek, MD) · 646-888-4189
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

    Contact: Study coordinator (Andrea Cercek, MD) · 646-888-4189
  • Memorial Sloan Kettering Cancer Center at Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States

    Contact: Study coordinator (Andrea Cercek, MD) · 646-888-4189
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

    Contact: Study coordinator (Andrea Cercek, MD) · 646-888-4189
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

    Contact: Study coordinator (Andrew Cercek, MD) · 646-888-4189
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

    Contact: Study coordinator (Andrea Cercek, MD) · 646-888-4189
Study leads
  • Andrea Cercek, MD

    Principal Investigator

    Memorial Sloan Kettering Cancer